05 April 2024
05 April 2024
NICE found that Smith+Nephew’s single-use negative pressure wound therapy results in fewer complications and is as cost-effective as the standard of care.
The primary goal of the trial is to evaluate the safety and tolerability of a single intravenous dose of ECUR-506.
The Phase II KICKSTART trial did not meet its primary endpoint, with the company now pivoting to other pipeline candidates.
The trial will assess the safety, tolerability, and immunogenicity of varying dosages of the vaccine.
The trial is scheduled to commence in the second quarter of this year.
The double-blind, randomised, multicentre trial will assess the safety and effectiveness of MK-1084 plus Keytruda.
Incannex anticipates a smooth cash runway as it prepares for a Phase IIb IND submission for generalised anxiety disorder.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
